The Top 5 Biosimilars Articles for the Week of February 25
The Center for Biosimilars® recaps the top news for the week of February 25, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 25.
Number 5: New psoriasis treatment guidelines say that anti—tumor necrosis factor biosimilars can be considered therapeutically interchangeable with their reference products.
Number 4: A newly published paper looks ahead to the potential for—and challenges related to—biosimilars of products like gene and cell therapies.
Number 3: As part of its investigation into drug pricing, the Senate Finance Committee is launching a bipartisan probe into insulin prices.
Number 2: Sandoz has filed suit against Amgen, asking the court for a declaratory judgment of patent noninfringement and invalidity.
Number 1: A judge has directed Boehringer Ingelheim to disclose its launch plans for its biosimilar adalimumab as part of a long-running patent dispute with AbbVie.
Finally, last week, our e-newsletter asked which stakeholder group you think has the most influence in combatting misinformation on biosimlars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
